Crossmark

Lerociclib plus fulvestrant in patients with HR+/HER2− locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy: LEONARDA-1 a phase III randomized trial

Crossref DOI link: https://doi.org/10.1038/s41467-025-56096-2

Published Online: 2025-01-16

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Xu, Binghe https://orcid.org/0009-0009-6827-2268
Zhang, Qingyuan

Luo, Yang

Tong, Zhongsheng

Sun, Tao https://orcid.org/0000-0001-5931-386X
Shan, Changping

Liu, Xinlan

Yao, Yumin

Zhao, Bing

Wang, Shusen https://orcid.org/0000-0003-0139-5780
Zeng, Xiaohua

Hu, Changlu

Yan, Xi

Wang, Xiaojia https://orcid.org/0000-0002-7005-0842
Jia, Hongyan

Chen, Zhendong

Qiu, Fuming

Wu, Xinhong

Zhang, Deyong

Li, Tong
License Information

Text and Data Mining valid from 2025-01-16

Version of Record valid from 2025-01-16
More Information

Article History

Received: 28 December 2023

Accepted: 9 January 2025

First Online: 16 January 2025

Competing interests

: The authors declare the following competing interests: B.X. discloses receiving advisory fees from Novartis and AstraZeneca. D.Z. and T.L. were employees of Genor Biopharma at the time of the study. The other authors declare no competing interests.

Document is current

Any future updates will be listed below